A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis
Latest Information Update: 15 Oct 2024
At a glance
- Drugs LTP 001 (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 10 Oct 2024 Status changed from active, no longer recruiting to discontinued.
- 27 Sep 2024 Planned End Date changed from 26 Sep 2024 to 19 Nov 2024.
- 06 Aug 2024 Planned End Date changed from 12 Aug 2024 to 26 Sep 2024.